KAHOUNOVA, Zuzana, Daniela KURFURSTOVA, Jan BOUCHAL, Gvantsa KHARAISHVILI, Jiri NAVRATIL, Ján REMŠÍK, Šárka ŠIMEČKOVÁ, Vladimír ŠTUDENT, Alois KOZUBÍK and Karel SOUČEK. The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition. Cytometry Part A. Hoboken: Wiley, 2018, 93A, No 9, p. 941-951. ISSN 1552-4922. Available from: https://dx.doi.org/10.1002/cyto.a.23101.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition
Authors KAHOUNOVA, Zuzana, Daniela KURFURSTOVA, Jan BOUCHAL, Gvantsa KHARAISHVILI, Jiri NAVRATIL, Ján REMŠÍK (703 Slovakia, belonging to the institution), Šárka ŠIMEČKOVÁ (203 Czech Republic, belonging to the institution), Vladimír ŠTUDENT (203 Czech Republic), Alois KOZUBÍK (203 Czech Republic, belonging to the institution) and Karel SOUČEK (203 Czech Republic, belonging to the institution).
Edition Cytometry Part A, Hoboken, Wiley, 2018, 1552-4922.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW Full Text
Impact factor Impact factor: 3.433
RIV identification code RIV/00216224:14310/18:00107868
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1002/cyto.a.23101
UT WoS 000445603300008
Keywords in English fibroblast activation protein; fibroblast surface protein; anti-fibroblast; epithelial-to-mesenchymal transition; cancer-associated fibroblasts
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 29/4/2020 11:25.
Abstract
The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein , and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein ) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised.
Links
EE2.3.20.0003, research and development projectName: Algebraické metody v geometrii s potenciálem k aplikacím
GA15-11707S, research and development projectName: Centrosomální abnormality u lidských pluripotentních kmenových buněk.
Investor: Czech Science Foundation
NV15-33999A, research and development projectName: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
PrintDisplayed: 26/5/2024 20:51